Biocon launches liraglutide in UK for diabetes, obesity
Biocon (BSE: 532523) has launched its Liraglutide, a GLP-1 peptide, in the United Kingdom for treating both diabetes and obesity. The drug-device combination will be marketed as Liraglutide Biocon for diabetes and Biolide for chronic weight management. This follows approval from the UK's Medicines and Healthcare Products Regulatory Agency, making Biocon the first generics company to gain approval for gLiraglutide in a major regulated market. Biocon's CEO, Siddharth Mittal, highlighted the company's commitment to affordable healthcare and its focus on expanding its GLP-1 product reach into other markets, according to the company.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
News Alerts
Get instant email alerts when Biocon publishes news
Free account required • Unsubscribe anytime